Avalo Therapeutics, Inc. - 10-Q Filing

Avalo Therapeutics reports Q3 2026 financial results including derivative liability valuations and preferred stock classifications.

SEC EDGAR ·

Tickers: $AVTX

Read the full article at SEC EDGAR

More Regulatory news